Cytokinetics, Incorporated announced that its FDA‑approved cardiac myosin inhibitor MYQORZO (aficamten) is now available for prescription in the United States. The drug will be offered in 5 mg, 10 mg, 15 mg and 20 mg tablet strengths, giving prescribers flexibility to tailor therapy to individual patient needs.
The company has activated a Risk Evaluation and Mitigation Strategy (REMS) program and a specialty pharmacy distribution network to support the launch. The REMS program will monitor patients for heart‑failure risk and requires echocardiographic assessments before and during treatment, ensuring safe use of the medication.
This launch marks the first commercial availability of a product that has been in development for decades and is Cytokinetics’ sole revenue‑generating asset. The availability of MYQORZO is a critical milestone for the company, enabling it to begin generating cash flow and to execute its commercial strategy in the hypertrophic cardiomyopathy market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.